2021PubMedOpen access

BLM interaction with EZH2 regulates MDM2 expression and is a poor prognostic biomarker for prostate cancer.

Yong Ruan, Houqiang Xu, Xinqin Ji, Jiafu Zhao

Open full text 20 citations

Abstract

observations. Our results demonstrated that the expression of P53 is affected by the binding of BLM and EZH2 to the MDM2 promoter region. This finding indicated that EZH2 regulates the expression of MDM2 at the transcriptional level by interacting with BLM.

About this research paper

What this paper is about

observations. Our results demonstrated that the expression of P53 is affected by the binding of BLM and EZH2 to the MDM2 promoter region. This finding indicated that EZH2 regulates the expression of MDM2 at the transcriptional level by interacting with BLM.

Why it matters

OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

observations. Our results demonstrated that the expression of P53 is affected by the binding of BLM and EZH2 to the MDM2 promoter region. This finding indicated that EZH2 regulates the expression of MDM2 at the transcriptional level by interacting with BLM.

Key concepts: Gene knockdown, EZH2, Cancer research, Prostate cancer, Mdm2, In vivo, Biology, Cancer

Related papers

Back to paper searchBrowse research topicsOriginal source
BLM interaction with EZH2 regulates MDM2 expression and is a poor prognostic biomarker for prostate cancer. — Research Paper | ScholarLens